Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Lilly agree partnership with Joslin Diabetes Center

Pfizer and Lilly agree partnership with Joslin Diabetes Center

7th October 2013

Pfizer and Lilly have entered into a new research collaboration with the Joslin Diabetes Center, a Boston-based not-for-profit institution affiliated with Harvard Medical School.

The alliance will allow all three organisations to accelerate research aimed at predicting kidney failure in patients with type 2 diabetes, while also developing potential ways to treat and prevent this condition.

It is the first time two pharmaceutical companies have allied with Joslin to identify biomarkers for predicting kidney disease, with the centre's genetics and epidemiology head Dr Andrzej Krolewski set to lead the research.

The work will involve the analysis of samples from a unique biorepository collected and studied by Dr Krolewski over a period of 15 years.

Dr Christelle Perros-Huguet, chief scientific officer of Pfizer's inflammation and remodelling research unit, said: "Pfizer is pleased to be a part of this research initiative. The longitudinal sample collection that Dr Krolewski and colleagues have assembled from patients with type 2 diabetes and renal function decline is a unique resource."

This comes after Pfizer agreed a new diabetes and obesity collaboration with the Sanford-Burnham Medical Research Institute in August 2013.ADNFCR-8000103-ID-801646311-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.